Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI +1.75%63 ROC (Joel Greenblatt) % is 3.73% as of Mar. 2026, which is 90% below its 10-year median of 35.71. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹69.34 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 62.59% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Balaxi Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.73%.
The historical rank and industry rank for Balaxi Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:BALAXI'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -13049.15 Med: 35.71 Max: 158.55
Current: 4.01
During the past 12 years, Balaxi Pharmaceuticals's highest ROC (Joel Greenblatt) % was 158.55%. The lowest was -13049.15%. And the median was 35.71%.
NSE:BALAXI's ROC (Joel Greenblatt) % is ranked worse than 62.59% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs NSE:BALAXI: 4.01
Balaxi Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -49.10% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Balaxi Pharmaceuticals ROC (Joel Greenblatt) % Related Terms
Balaxi Pharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Balaxi Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BALAXI vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 3.73% mean?
Balaxi Pharmaceuticals (NSE:BALAXI) has a ROC (Joel Greenblatt) % of 3.73% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Balaxi Pharmaceuticals and its competitors. This is 90% below median its historical median of 35.71. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #614 out of 981 companies in the Drug Manufacturers industry, placing it in the top 62.6%.
Is Balaxi Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Balaxi Pharmaceuticals' current ROC (Joel Greenblatt) % of 3.73% is 90% below median its 10-year median of 35.71. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Balaxi Pharmaceuticals' value of 3.73% is 67.5% below this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #614 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #614 out of 981 companies for ROC (Joel Greenblatt) %. This places Balaxi Pharmaceuticals in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. Balaxi Pharmaceuticals' value of 3.73% is 67.5% below this benchmark. While the company's 10-year median is 35.71 vs. the industry median of 11.46, Balaxi Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current ROC (Joel Greenblatt) % of 3.73% is 67.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current ROC (Joel Greenblatt) % is 3.73%, which is 90% below median its own 10-year median of 35.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.34, compared to a current price of ₹24.42 — trading 64.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 3.73%, which is 90% below median its 10-year median of 35.71 and 67.5% below the Drug Manufacturers industry median of 11.46. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current ROC (Joel Greenblatt) % is 3.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.42 is trading 64.8% below its estimated GF Value™ of ₹69.34.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
ROC (Joel Greenblatt) %: 3.73% (90% below median its 10-year median of 35.71)
GF Value™: ₹69.34 vs. price of ₹24.42 (64.8% below fair value)
Industry Position: 67.5% below the Drug Manufacturers median (#614 of 981)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score
Get the complete analysis for NSE:BALAXI
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
